tuneTypical Dose
Often 20 to 60 mEq/day in divided doses, adjusted to urine chemistry and tolerance
Mineral
Potassium Citrate
Potassium citrate
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Urine chemistry can shift quickly, while stone-prevention benefit is assessed over months.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Potassium citrate is primarily a urinary-alkalinization and kidney-stone-prevention tool, not a generic wellness electrolyte supplement.
Potassium citrate has a much clearer clinical role than many supplements. It is mainly used to increase urinary citrate and urine pH in people with recurrent calcium stones or uric acid stone risk. The human evidence for stone prevention is real. The main limitation is safety, because potassium handling can become dangerous in kidney disease or when combined with medications that raise potassium.
Potassium citrate increases urinary citrate and alkalinizes urine, reducing conditions that favor certain kidney stones. Its core mechanism is urinary-chemistry modification, not a broad systemic wellness effect.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced recurrence of calcium-containing kidney stones
- Increased urinary citrate and urine alkalinization
Secondary Outcomes
- Not appropriate as a casual general-potassium supplement
Safety
Contraindications and Interactions
Contraindications
- Chronic kidney disease with impaired potassium excretion
- Existing hyperkalemia
- Use of potassium-sparing diuretics without supervision
Side effects
- GI upset
- Nausea
- Hyperkalemia
Interactions
- ACE inhibitors, ARBs, or potassium-sparing diuretics
Avoid if
- You have kidney disease without clinician guidance
- You are using it as a casual electrolyte supplement
- You cannot monitor potassium risk when indicated
Evidence
Study-level References
pc-SRC-001Systematic review and meta-analysis
Sourceopen_in_newPhillips R, Hanchanale V, Myatt A, et al. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015;(10):CD010057. doi:10.1002/14651858.CD010057.pub2. PMID:26439475.
Population: Adults with calcium-containing kidney stones enrolled in randomized trials of citrate salts.
Dose protocol: Various citrate-salt regimens, mainly potassium citrate
Key findings: Reduced recurrent calcium stone formation and improved stone outcomes versus control.
Notes: Main Cochrane evidence anchor.
Paper content
This Cochrane review is the main evidence anchor for potassium citrate. Citrate salts, mainly potassium citrate, reduced recurrent calcium stone formation and improved stone outcomes versus control, although gastrointestinal side effects and treatment discontinuation were more common. That supports potassium citrate as a real stone-prevention tool rather than a generic wellness mineral.
pc-SRC-002Systematic review and meta-analysis
Sourceopen_in_newXiong T, Turner RM, Wei L, et al. Effect of potassium citrate supplement on stone recurrence before or after lithotripsy. Systematic review and meta-analysis. Int J Urol. 2017;24(1):13-20. doi:10.1111/iju.13241. PMID:27915395.
Population: Adults with kidney stones before or after lithotripsy in randomized and controlled trials of potassium citrate.
Dose protocol: Various potassium citrate regimens before or after lithotripsy
Key findings: Reduced stone recurrence compared with control.
Notes: Potassium-citrate-specific modernization source.
Paper content
This meta-analysis reinforces the core clinical role of potassium citrate in calcium-stone prevention. It is especially useful as a modernization source because it focuses specifically on potassium citrate rather than broader citrate salts.
pc-SRC-003Umbrella review of systematic reviews and meta-analyses.
Sourceopen_in_newVeronese N, Ciriminna S, Errera CM, et al. Preventing and treating kidney stones: an umbrella review of meta-analyses of non-surgical randomized controlled trials. Minerva Urol Nephrol. 2025;77(4):472-478. doi:10.23736/S2724-6051.25.06296-2. PMID:40891477.
Population: Adults with kidney stones across 9 systematic reviews comprising 88 RCTs with 27,286 participants.
Dose protocol: Umbrella review synthesizing 9 meta-analyses (88 RCTs, 27,286 participants).
Key findings: Potassium citrate reduced nephrolithiasis recurrence by 79%, supported by high-level GRADE evidence.
Notes: Highest-tier evidence synthesis available. Confirms potassium citrate as one of the most effective non-surgical stone-prevention interventions.
Paper content
This 2025 umbrella review synthesized 9 systematic reviews covering 88 RCTs with 27,286 total participants to evaluate non-surgical approaches for kidney stone prevention and treatment. For potassium citrate specifically, the review found a 79% reduction in nephrolithiasis recurrence, rated with high-level evidence according to the GRADE framework. This is the most comprehensive synthesis available, confirming potassium citrate's position as one of the most effective non-surgical interventions for recurrent kidney stones. The umbrella design provides the highest tier of evidence synthesis for this indication.